

# Index

T, Table; F, Figure

## A

- abdominal pain 375
- acetaminophen (APAP)  
413–414
- acute lymphoblastic leukemia (ALL) 41–54
- autologous HSC/BMT 53
- contraindications to transplant 53
- indications for transplant 52–53
- chemotherapy vs. HLA-identical siblings BMT 49–50
- children 52
- adolescents, outcome on UK national pediatric/adult trials 44
- special aspects 53
- classification 41–42
- French–American–British (FAB) 41
- clinical relevance of minimal residual disease (MRD) in adults 43
- GOELAMS trial 51
- HLA-identical family member transplant 52
- HLA-identical unrelated donor transplant 53
- lymphoma /CLL 216T  
DLI 219–220
- monitoring posttransplant 54
- pretransplant workup 53
- prognostic factors 42
- results
- allogeneic transplant 47–52
  - CIBMTR data 47
  - conventional therapy in adults 43–46
  - outcome, 609 adults after relapse 45
  - treatment algorithm for adults 53
- acute mixed lineage leukemia 29
- acute myeloid leukemia (AML) 25–39, 218
- AML/MDS, relapse 215T
- autologous transplant 35, 37
- vs. HLA-matched unrelated donor (URD) 34
- CEBPA mutation 29
- CIBMTR database results 36
- classification 25
- French–American–British (FAB) 25
- common cytogenetic abnormalities, prognostic impact 26
- cytochemical, cytogenetic and immune phenotype features 29
- FLT3 ITD mutation 29
- high risk BMT/SCT
- refractory first relapse 277
  - second remission 277
- indications for transplant 37–38
- children 38
- comorbidities are important for outcome 38
- HLA-identical family member transplant 37
- HLA-identical unrelated donor transplant 37
- matched unrelated transplants 32–33
- transplant in elderly patients 37
- molecular abnormalities and their prognostic impact 27
- monitoring posttransplant 39
- myelodysplastic therapy-related syndrome (t-MDS) 33
- NPM1 mutation 29
- other variants 29
- outcome of induction and postremission therapy in younger adults 30
- pretransplant workup 39
- prognostic factors 29–30
- related neoplasms 27–28
- results with allogeneic and autologous transplant 32
- results with non-transplant therapy in adults 30
- treatment
- consolidation in remission 39
  - induction 39
  - relapsed or refractory AML 39
  - treatment algorithm 39
- acute undifferentiated leukemia 29
- acyclovir 244, 478–479
- addressins 16
- adhesion molecules 12, 15
- adoptive immunotherapy, tumor-infiltrating lymphocytes (TILs) 224
- adrenocorticotrophic hormone, SIADH 370
- adrenoleukodystrophy, X-linked (X-ALD) 192–194
- albumin, human serum albumin 266, 272
- alemtuzumab 391, 491–492
- alkylating agents 459
- allogeneic transplants
- complications 4
  - donor choice 243
  - donor mortality 4
  - donor workup 243
  - reporting 3
  - results
  - Dynamic International Prognostic Scoring System 63

- allogeneic transplants (cont.)  
   myeloproliferative  
   syndromes 63–64  
 alloimmune hemolysis 262  
 allopurinol 244  
 alpha-mannosidosis 192  
 alveolar hemorrhage, diffuse  
   (DAH) 400  
 American Society for Blood  
   and Marrow  
   Transplantation 5, 525  
 American Society of  
   Hematology 525  
 amikacin 422  
 aminoglycosides 422–425  
   contraindications and  
   adverse effects 424  
   drug interactions 424  
   general prescribing 424  
   preparations available and  
   dosage 422  
 amitriptyline 421–422  
 amlodipine 488  
 amoxicillin 431  
 amoxicillin/clavulanate  
   426–427  
 amphotericin 452–454  
 amphotericin B 453  
 amphotericin deoxycholate 453  
 amphotericin suspension 455  
 ampicillin 432  
 amyloidosis 133–137  
   classification 133  
   contraindications for  
   transplant 136  
   conventional therapy  
   134  
   defined 133  
   follow-up 137  
   indications for  
   transplantation 136  
   nephrotic syndrome 135  
   reduced-intensity allogeneic  
   transplant 136  
   results  
   autologous transplant  
   134–136  
   melphalan and autologous  
   transplant 135  
   risk factors, transplant-  
   related mortality 135  
   secondary to multiple  
   myeloma 136  
   staging 135  
 analgesics 413–419  
   adjuvant 420
- ancestim 8  
 anemia  
   causes after BMT 384–385  
   refractory anemia with excess  
   blasts-1 (RAEB-1) 78  
   *see also* aplastic anemia  
 anidulafungin 451  
 anthracenediones 466–468  
 anthracyclines 80, 466–468  
   conversions 367  
 antibacterials, prophylaxis 345  
 antibiotics 422–444  
   empiric 331  
 anticonvulsants 420  
   drug interactions 420  
 antidepressants (TCAs) 421–422  
 antidiarrheals 444–445  
 antiemetics 254–255, 255T,  
   445–446  
 antifungals  
   persistent fever 332–333  
   prophylaxis 345  
   systemic 340T, 448–454  
   topical oral use 454–456  
   topical and systemic use  
   456–458  
   treatment, notes 341  
   *see also* azoles;  
   echinocandins; polyene  
   macrolides; pyrimidines  
 antigen presentation by  
   MHC 14  
   dendritic cells 20, 221–222  
 antigen-specific antibody,  
   T-cell–B-cell  
   collaboration 14  
 antimetabolites 468–478  
 antineoplastics 459–478  
   neurotoxicity 390  
 antithymocyte globulin  
   (ATG) 166  
   GVHD prevention 313  
   horse 483–484  
   rabbit 484  
   steroid-refractory GVHD 315  
 antivirals 478–483  
   prophylaxis 346  
 aplastic anemia 165–171  
   allogeneic transplant,  
   indications 170  
   antithymocyte globulin  
   (ATG) 166  
   combination immune  
   suppressive treatment  
   166  
   conditioning regimen 284
- etiology 165–166  
   HLA-identical sibling  
   transplant 168  
   HLA-identical unrelated  
   donor transplant  
   169–170  
   methylprednisolone 166  
   monitoring posttransplant 170  
   pretransplant workup 170  
   results  
   allogeneic transplants 168  
   conventional therapy 166  
   staging 166  
   triple immune suppressive  
   therapy 167  
*Appendix* 525–528  
   patient-oriented databases  
   and sources of  
   information 527–528  
   periodicals 527  
   textbooks 526–527  
   websites and organizations  
   525–526  
 apreptant 255, 445–446  
 arrhythmias 367  
 arthralgia 385, 387  
 asparaginase 476–477  
 atovaquone 440–441  
 atropine 444  
 autoimmune disorders 205–207  
   future perspectives 207  
 autologous transplants 3  
   ALL 53  
   AML 32, 35, 37  
   amyloidosis 134–136  
   bone marrow/peripheral  
   blood stem cell infusion  
   262–263  
   CLL 72, 74  
   CML 62, 72  
   conditioning regimens  
   282–283  
   diffuse large B-cell  
   lymphoma (DLBCL) 95  
   follicular NHL 100–102  
   Hodgkin lymphoma (HL)  
   115–117, 119–120  
   mantle cell lymphoma  
   99–100  
   mobilization of autologous  
   blood stem cells  
   240–241  
   multiple myeloma 3, 125–128  
   multiple sclerosis 206  
   myelodysplastic syndrome  
   (MDS) 82, 88

- axitinib 147  
azacitidine 218, 474  
  efficacy 81  
  myelodysplastic syndrome (MDS) 81  
azo dye 28  
azoles 448–451  
  contraindications and adverse effects 449  
  drug interactions 450  
  general prescribing information 450–451  
aztreonam 431
- B**
- B-cell neoplasms, WHO 90T  
bacteremia 334  
BAFF concentrations 300  
basiliximab, TA-TMA 358  
BEAM 120  
beta-lactams 426–427  
bevacizumab 147  
bilirubin 272  
Billingham's postulates, graft-vs.-host disease (GVHD) 298  
biopsies  
  acute GVHD 315  
  chronic GVHD 315  
BK virus, hemorrhagic cystitis 351–353  
bladder, grading toxicity 275  
bladder irrigation 352  
bleeding 376  
bleomycin 477–478  
blindness, cyclosporin-associated 359  
blood  
  red blood cell recovery 349  
  white blood cell (WBC) count 271  
  *see also* hematopoietic (progenitor/stem) cell transplant (HCT)  
Blood and Marrow Transplant Clinical Trials Network (BMTCTN) 101, 280, 526  
blood transfusion 264  
  complications 264  
  fresh frozen plasma 267  
  infectious disease transmission 264  
  packed red cell transfusion 265
- bone  
  osteomyelitis 385  
  osteonecrosis 385  
  osteoporosis 385  
bone marrow  
  allogeneic donor graft source 3  
  cell dose 258  
  donor 256  
  obese donors 257  
  harvest 256  
  infusion 262–263  
  ABO-compatible 261  
  ABO-incompatible 260–262  
  major ABO-incompatible 261–262  
  minor ABO-incompatible 262  
  transfusion guidelines 260–262  
  long-distance transportation 258–260  
  microenvironment 11  
  recipient 256  
  vs. stem cells 3  
Bone Marrow Donors Worldwide 526  
bortezomib 125, 130, 134, 492–493  
brain disease  
  diffuse 387  
  focal 387  
brentuximab 493  
bronchiolitis, pulmonary  
  chronic GVHD/BO/BOS 401–402  
bronchoalveolar lavage 403  
Burkitt's lymphoma 106  
busulfan 390, 459–460
- C**
- calcineurin inhibitor 488  
calcineurin inhibitor-associated hypertension 359  
  treatment 359  
calcineurin-related neurotoxicity 391–392  
calcium channel blockers, cyclosporin-associated blindness 359  
carbapenems 427–428  
carboplatin 460–461  
cardiac grading of toxicity 275
- cardiovascular complications of HSCT 366–369  
  arrhythmias 367  
  cardiac and cerebral events 368  
  congestive heart failure 366  
  cumulative incidence 368  
carmustine (BCNU) 461–462  
casposungin 451  
catheter  
  capping and flushing 248–249  
  central venous catheter management 245–253  
  difficulty in sampling 250–251  
  drawing blood from 248–249  
  exit site dressing 247–248  
  infections 252–253  
  insertion 246  
  postoperative care 246  
  preoperative/local anesthetic preparation 246  
  malfunction due to clotting 251–252  
  management of dislodged catheter 247  
  management of non-functioning catheter 250–253  
  potential problems 252–253  
  removal 250  
  right atrial catheters 245–253  
  safe management 247  
  streptokinase/urokinase/TPA instillation 252  
catheter-related bloodstream infections (CRBSI) 335, 335T  
  complications 336  
CD antigens 15  
CD34 stem cells 20  
CD40 ligand (CD40L) 15  
CD73 and CD105 23  
CD314 221  
cefazolin 429  
cefepime 430  
ceftriaxone 429  
cell cycle 13  
  p53, HSC activity 13  
cellular therapy 209–225  
Center for International Blood and Marrow Transplantation Research 525

- central venous catheter 245–253
- cephalexin 429
- cephalosporins 429–430
- chaperon mediated therapy (CMT) and gene therapy 198, 201
- chelation therapy  
assessment 189  
iron overload 181
- chemokines 17  
leukapheresis 241
- children's play scale 275
- chimeric antigen receptors (CARs) 224
- chronic granulomatous disease 175
- chronic lymphatic leukemia (CLL) 67–75  
autologous HSC/BMT 74  
Binet classification 68  
chemoimmunotherapy 70  
CIBMTR data 73  
contraindications to transplant 74  
cytogenetic findings 68  
immune phenotype and cytogenetic abnormalities 68  
indications for transplant 74  
monitoring posttransplant 75  
pretransplant workup 75  
prognostic factors 68  
conventional therapy 69  
Rai classification 67  
reduced-intensity conditioning (RIC) 73
- results  
with allogeneic transplant 71–72  
allogeneic transplants in different series 73–74  
with autologous transplant 72  
with conventional therapy 69–70
- Richter's transformation to NHL 73
- special problems in transplantation 72–73
- staging 67
- treatment recommendations 70
- chronic myeloid leukemia (CML) 3, 56–65, 217–218
- allogeneic transplant  
indications 64–65  
treatment failure as defined 64
- allogeneic transplant results 60–62  
children 62  
failure with tyrosine kinase inhibitors 61  
initial cell dose 62  
with reduced intensity 63  
relapse 61–62, 215F
- alpha-interferon 58
- autologous transplant results 62
- BCR-ABLI mutations 61
- CIBMTR data 60
- classification 56
- contraindications to transplant 65
- dasatinib 58
- definitions 58
- donor lymphocytes in combination with IFN and GM-CSF 217–218
- EBMT risk score 57
- imatinib 58, 218
- monitoring posttransplant 65
- nilotinib 58
- Philadelphia chromosome  
absent/present 56
- pretransplant workup 65
- prognostic factors with conventional therapy 57–58
- relapse 212T
- relapse after allogeneic transplant 61–62, 215T
- results with standard therapy 58–59
- staging 57
- treatment algorithm 65
- tyrosine kinase inhibitors 3, 58
- CIBMTR data  
ALL 47  
AML 36  
CLL 73  
CML 60  
follicular NHL 103–105F  
HL 116, 119  
MDS 86–87  
multiple myeloma 130
- cidofovir 479
- CIP/KIP family 13
- ciproflaxin 435
- clindamycin 434
- Clostridium difficile* infection (CDI) 338–339, 339T
- clotrimazole 455–456
- CMV, pre-emptive treatment for asymptomatic CMV 346
- co-trimoxazole 244
- codeine 415, 419
- complications of HSCT, organ-related 366–405  
*see also* complications of HSCT, transplant-related (*below*)
- bleeding 376
- cardiac and vascular 366–369
- cardiovascular 366–369
- dermatologic 369–370
- diarrhea and abdominal pain 375
- dysphagia/odynophagia 375
- endocrine 370–372
- eye 372
- gastrointestinal 374–379
- hematologic 384–385
- hepatobiliary complications and iron overload 376–379
- hepatotoxic drugs posttransplant 378
- ileus 376
- infertility/preserving fertility 380–384
- liver function abnormalities 377
- musculoskeletal 385–387
- nausea/vomiting 374
- neurologic 387–395
- perianal 396
- psychosocial 396–397
- pulmonary 397–404
- renal 404–405
- comorbidity index 237–238
- complications of HSCT, transplant-related 348–366
- allogeneic transplants 4
- calcineurin inhibitor-associated hypertension 359
- graft failure after allogeneic HSCT 348–366
- growth and development 359–360
- hemorrhagic cystitis 350–351

- hepatic veno-occlusive disease (VOD) 353
- secondary malignancies 361–366
- transplant-associated thrombotic microangiopathy (TA-TMA) 357–358
- conditioning regimens for HCT 282–286
- fluid regimes 254–256
- congenital immunodeficiencies 172–177
- contraindications for allogeneic transplant 177
- gene therapy 177
- indications for allogeneic transplant 177
- non-SCID immunodeficiencies 173
- BMT results 174–176
- cumulative probability of survival 176
- reduced-intensity conditioning 177
- SCID BMT results 173–174
- mutations 173
- screening 173
- congestive heart failure 366
- grading 373
- CORAL (Collaborative Trial in Relapsed Aggressive Lymphoma) study 96–97
- prior rituximab therapy 95
- cord, *see also* umbilical cord blood (UCB)
- Cord Blood Forum 526
- cord blood unit 3
- cornea, complications of HSCT 372
- corticosteroids 390, 484–486
- cortisone acetate 484
- Cotes formula 478
- creatinine 271
- TA-TMA 358
- creatinine clearance rate 271
- Crohn's disease 207
- cryopreservation technique 242
- cryptococcosis 344
- Cushing syndrome 370–371
- cyclin D–Cdk4/6 complex 13
- cyclin E–Cdk2 13
- cyclophosphamide 390, 462–463
- MDS 80
- cyclosporin 390, 486–488
- calcineurin inhibitor-associated hypertension 359
- GVHD complications prevention 322
- GVHD prevention 313
- cyclosporin-associated blindness 359
- cystatin C, TA-TMA 358
- cystitis *see* hemorrhagic cystitis
- cytarabine 468–469
- cytokine helper T-cells 16
- cytokine induced killer (CIK) cells 221
- cytokine storm 211, 299
- GVHD 299
- cytokines 16
- leukapheresis 241
- production by helper T-cells 16
- cytosine arabinoside 390
- CNS leukemia pretransplant 245
- cytotoxic drugs administration 280–281
- extravasation 281
- D**
- dacarbazine 463–464
- daclizumab acute steroid-refractory GVHD 315
- TA-TMA 358
- dapsone 440–441
- daptomycin 434–435
- darbepoetin 8
- dasatinab 58
- dasatinib 494
- daunorubicin 466–468
- for extravasation antidote 281
- decitabine 218, 474
- defibrotide 356, 497
- TA-TMA 358
- dendritic cells 20, 221–222
- cross presentation 211
- leukemia origin differentiation 217
- stimulation 211
- denileukin diftitox, acute steroid-refractory GVHD 316
- dermatologic complications of HSCT 369–370
- dexamethasone 484
- dextrazoxane, extravasation antidote 281
- DHAP 119
- Hodgkin lymphoma (HL) 119
- diarrhea, complication of HSCT 375
- diffuse alveolar hemorrhage (DAH) 400
- diffuse large B-cell lymphoma (DLBCL) 94–98
- allogeneic HCT for relapsed/refractory DLBCL 97
- autologous HCT conditioning regimens 97–98
- first complete remission (CRI) 95
- for relapsed/refractory DLBCL 95
- International Prognostic Index (IPI) 94F
- involved field radiotherapy (IFRT) posttransplant 98
- Revised-IPI 94–95F
- salvage regimens used prior to HCT 95–97
- DHAP 95
- EPOCH 95
- ESHAP 95
- GDP 95
- GemOx 95
- ICE 95
- MINE 95
- diphenoxylate 444
- discharge planning 269–270
- dolasetron 447
- donor lymphocyte infusions (DLI) 209–225
- elimination of leukemia stem cells 220
- GVHD 211
- high risk AML/MDS 216T
- preemptive 218
- for relapse of AML 218–219
- T-cell depletion 211
- doxorubicin 466–468
- see also* daunorubicin
- Du Bois (1916) formula 271
- duloxetine 420
- dysphagia/odynophagia 375
- E**
- echinocandins 451–452
- ectropion, lid surgery 374
- eculizumab, TA-TMA 358

- emotional barriers of HSCT 396
- endocrine complications of HSCT 370–372
- enzyme replacement therapy (ERT) 198
- epileptic seizures, causes 389
- epidodophyllotoxins 472–478
- myelodysplastic syndrome (MDS) 80
- EPOCH, salvage regimen 95
- epoetin 8
- ESHAP
- Hodgkin lymphoma (HL) 119
- salvage regimen 95, 119
- esophagus, dysphagia/odynophagia 375
- estrogen, dosages 380
- etanercept 497–498
- etoposide 390, 472–473
- European Group for Blood and Marrow Transplantation 525
- HCT for 2009 3
- everolimus 147
- Ewing sarcoma 161–162
- long-term outcome 162
- extracorporeal photopheresis (ECP), acute steroid-refractory GVHD 316
- extravasation antidote
- for daunorubicin 281
- for dexrazoxane 281
- for mustine 281
- for vinca alkaloids 281
- extravasation of cytotoxic drugs 281
- eye complications of HSCT 372
- grading of ocular GVHD 373
- treatment of ocular GVHD 373
- eyelid surgery, ectropion 374
- F**
- famciclovir 478–479
- Fanconi anemia, IPS cells 223
- fasciitis 386
- female fertility/hormonal problems 379–384
- fentanyl 415
- transdermal patches 419
- fertility after HSCT 380–384
- fever
- defined 331
- and neutropenia 330–333
- of unknown origin (FUO) 332–333
- fibroblast growth factor (FGF-2) 21
- filgrastim 8
- fluconazole 244, 448
- flucytosine 454
- fludarabine 469–470
- fludrocortisone 485
- fluid regimes, conditioning regimens 254–256
- fluoroquinolones 435–438
- contraindications and adverse effects 436
- drug interactions 436
- general prescribing information 437
- folinic acid 501
- follicular NHL 100–102
- alloHCT 101
- Blood and Marrow Transplant Clinical Trials Network (BMTCTN) 101
- CIBMTR data 103–105F
- FLIPI 100–101, 101F
- fosaprepitant 445–446
- foscarnet 244, 480
- Foundation for the Accreditation of Cellular Therapy (FACT) 526
- fractalkine 17
- French–American–British (FAB) classification
- ALL 41
- AML 25
- myelodysplastic syndrome (MDS) 78
- G**
- G-CSF 8
- gabapentin 420
- ganciclovir 244, 480
- gastrointestinal complications of HSCT 374–379
- infections 336T
- GDP
- Hodgkin lymphoma (HL) 119
- salvage regimen 95, 119
- gemcitabine, dexamethasone and cisplatin (GDP) 119
- GemOx, salvage regimen 95
- gentamicin 422
- germ cell tumors, testis 139
- globoid cell leukodystrophy (Krabbe disease) 201
- glucarpidase 472
- GM-CSF 8, 217
- graft failure after allogeneic HSCT 349
- causes 349
- risk factors 350
- treatment and outcome 350
- graft-vs.-host disease (GVHD) 21, 303–305
- BAFF concentrations 300
- Billingham's postulates 298
- biomarkers 300
- cellular effectors 303
- CNS effects 395
- costimulatory molecules 301
- cytokine storm 299
- genetic basis of 298–300
- GVH reaction, history 297
- HLA matching 298
- HLA-KIR allo-recognition 299
- IFN-gamma 221, 302
- IL-2 production 302
- IL-10 suppression 302
- inflammatory effectors 303
- interleukin (IL)-10, common haplotypes of 299
- KIR receptors 299
- leukocyte migration 303
- minor histocompatibility antigens (HA) 298
- NOD2CARD15 gene polymorphisms 299
- non HLA genes 299
- pathobiology 297–305
- T-cells
- depletion 210
- migration of 303
- proliferation and differentiation 301
- regulatory suppression 302
- Th1 cytokines 302, 305
- Th1/Th2 paradigm of donor T-cells 305
- Toll-like receptors (TLRs) 303
- tumour necrosis factor (TNF) 299
- see also* graft-vs.-host disease (GVHD), acute and chronic, (*below*)
- graft-vs.-host disease (GVHD), acute 300–301, 311–317
- biopsies 315
- caused by naïve T-cells 302

- definition and staging 311–312  
 immunobiology 300–301  
 memory T-cells 302  
 organ staging 312  
 overall clinical grading 313  
 phase 1: activation of  
   antigen-presenting cells (APCs) 300  
 phase 2: donor T-cell  
   activation 301–303  
 phase 3: cellular and  
   inflammatory effector  
   phase 303  
 posttransplant  
   immunosuppression 313  
 prophylaxis 313  
 prophylaxis, novel agents 313  
 renal GVHD 405  
 secondary therapy 315–317  
 steroid-refractory 314–315, 317  
 suggested steroid taper 314  
 treatment 313–317  
 vs. chronic 297, 319  
 graft-vs.-host disease (GVHD),  
   chronic 303–305  
   ancillary/supportive care  
   interventions 324–326  
   biopsies 315  
   CNS/PNS, diagnostic  
   work-up 395  
   definition and staging  
   317–319  
   experimental models 304  
   myeloid aplasia 217  
   neurologic manifestations  
   392–395  
   NIH Consensus Diagnostic  
   Criteria 318  
   organ scoring 320–322  
   steroid-sparing therapies  
   323  
   treatment 322–326  
 graft-vs.-leukemia (GVL)  
   effects 18, 20, 210  
   T-cells 147–148  
 graft-vs.-tumor responses  
   148–153  
 granisetron 447  
 granulocyte disorders 175  
 granulocyte transfusion 266  
 griseofulvin 457–458  
   drug interactions 458  
 growth and development  
   cognitive deficiencies 360  
   hypogonadism 360  
   and TBI 359–360  
   growth factors, registered 8  
   growth hormone  
   deficiency 360  
   treatment, and tumors 360  
   guidelines, posttransplant  
   surveillance 107
- ## H
- haploidentical stem cell  
   transplant 277–280  
   advantages and  
   disadvantages 278  
   defined 277  
   GVHD 279  
   high risk, ALL 279  
   high risk, AML 279  
   indications 277  
   Johns Hopkins protocol 278  
   outcomes in different diseases  
   279  
   Perugia protocol 278  
   problems and solutions 280  
   recent developments 280  
   fetomaternal  
   microchimerism 280  
   killer immunoglobulin  
   receptor (KIR) 280  
   umbilical cord transplants  
   280  
 haptoglobin, TA-TMA 357  
 head and ENT (HEENT)  
   infections 336T  
 height, and TBI 360  
 hematologic complications of  
   HSCT 384–385  
 hematologic malignancy,  
   conditioning regimen 284  
 hematopoietic (progenitor/stem)  
   cell transplant (HCT)  
   advantages and  
   disadvantages 242  
   age limits 237  
   allogeneic donor  
   choice 243  
   mortality 4  
   workup 243  
   alloimmune hemolysis 262  
   antiemetics 255T  
   bilirubin 272  
   bladder toxicity 275  
   blood transfusion, guidelines  
   264  
   body surface area 273  
   bone marrow donation 256  
   cardiac toxicity 275  
   central venous catheter  
   management 245–253  
   chemosensitivity of disease  
   240  
   children's play scale,  
   Lansky 275  
   CNS 276  
   CNS leukemia pretransplant  
   cytosine arabinoside 245  
   hydrocortisone 245  
   liposomal cytosine  
   arabinoside 245  
   methotrexate 245  
   treatment 245  
   co-trimoxazole 244  
   conditioning regimens  
   282–286  
   allogeneic transplantation;  
   myeloablative 285–286;  
   reduced intensity  
   nonmyeloablative  
   283–284  
   antiemetic regime 254–255  
   aplastic anemia 284  
   autologous transplant  
   282–283  
   fluid regimens 254–256  
   hematologic malignancy  
   284  
   leukemia 282  
   lymphoma 282  
   myeloablative vs. reduced  
   intensity 285–286  
   myeloma 283  
   side effects 254  
   testicular cancer 283  
   thalassemia major 284  
   creatinine 271  
   creatinine clearance rate 271  
   cytotoxic drugs administration  
   280–281  
   extravasation 281  
   discharge planning 269–270  
   disease chemosensitivity  
   240–241  
   Du Bois (1916) formula 271  
   ECOG/WHO performance  
   status 274  
   eligibility criteria 277  
   exclusion criteria for  
   transplantation 237  
   fluconazole 244  
   fluid balance 268

- hematopoietic (progenitor/stem) cell transplant (HCT) (cont.)
- fluid regimes, conditioning regimens 254–256
  - formulas 271–273
  - foscarnet 244
  - fresh frozen plasma 267
  - ganciclovir 244
  - gastrointestinal 277
  - granulocyte transfusion 266
  - haploidentical stem cell transplantation 277–280
  - heart failure 237
  - height and weight 272
  - hematopoietic cell transplantation comorbidity index (HCT-1) 238
  - hemoglobin 271
  - hemolysis, alloimmune 262
  - hepatic toxicity 276
  - HSA + albumin 272
  - infection 237
  - Karnofsky performance score 274
  - kidney failure 237
  - leukapheresis 241
    - alternative cytokines/chemokines for stem cell mobilization 241
    - cryopreservation technique 242
  - liver failure 237
  - long-distance transport of bone marrow 258–260
  - marrow vs. stem cells 3
  - methotrexate, CNS leukemia pretransplant 245
  - mobilization of autologous blood stem cells 240–241
  - mouth care guidelines 268, 276
  - norfloxacin 244
  - oral hygiene 268–269
  - organ toxicity after BMT 275–277
  - pain relief 269
  - pentamidine 244
  - performance status, ECOG/WHO 274
  - platelet count 271
  - platelet refractory patients 266
  - platelet transfusion 265–266
  - practical aspects 235–286
  - pre-transplant evaluation 107–108
  - prediction of nonrelapse mortality (NRM) 239
  - prediction of overall survival (HCT-C1) 239
  - pretransplant workup 239–240
  - prophylactic medications 244
  - protocol for transplant day 256
  - pulmonary toxicity 276
  - radiation dose 272
  - readmission to hospital 270
  - renal toxicity 276
  - respiratory failure 237
  - routine tests 263
  - SCT-specific comorbidity index 237
  - secondary malignancies 103–105
  - surface area calculation 271
  - total parenteral nutrition 267–268
  - total-body irradiation 255–256
  - transplant frequency, Europe 3
  - transplant-related mortality 4
  - trimethoprim 244
  - vaccinations posttransplant 270–271
  - weight 272
  - white blood cell (WBC) count 271
  - workup, pretransplant 239–240
- hematopoietic recovery, defined 348
- hematopoietic stem cells (HSCs) 9–10, 209
- cell cycle activity 13
    - p53 13
  - differentiation, transcription factors 9, 209
  - growth factors 7–8
  - homing 12
  - numbers 297
  - phenotypic markers 9
  - registered growth factors 8
- hemoglobinopathies 179–190
- beta-thalassemia syndromes 179
- hemorrhagic cystitis 350–351
- BK virus 351–353
  - diagnosis 351
  - grading 351
  - prevention 352
  - treatment 352–353
- hepatic toxicity 276
- hepatic veno-occlusive disease (VOD) 353
- classification 354
  - diagnosis 354
  - differential diagnosis 354
  - outcome 355
  - pathogenesis 353
  - prophylactic treatment 355
  - risk factors 353
  - supportive treatment 356
  - treatment 356
- hepatitis, posttransplant 342
- hepatitis B 342
- hepatitis C, infected recipient 343
- hepatobiliary complications of HSCT 376–378
- hepatotoxic drugs posttransplant 378
- herpesvirus 341, 342T
- HERV-E antigens 154, 156
- histocompatibility antigens 210, 220
- histocompatibility typing 509–519
- HIV-related lymphoma 106
- HLA-KIR allo-recognition 299
- HLA-testing 509–523
- allogeneic transplantation 509
  - chimerism 519–521
    - categories 520
    - determination 521
    - mixed chimerism 519
    - monitoring 520
    - testing 520
  - class II genes, DRbeta1 genes 511
  - cytogenetic terminology 521–522
  - HLA class I and II molecules 510
  - HLA typing 509–519
  - HLA-A serology 512
  - HLA-B serology 513–514
  - HLA-C alleles 19
  - HLA-class I and class II serology 511–512
  - HLA-Cw serology 515–516
  - HLA-DPB1 common alleles 516–517



- HLA-DQB1 serology 517–518
- HLA-DRB1 serology 518–519
- HLA-DRB3, B4, B5 serology 519
- minimal residual malignant disease (MRD) 522–523  
detection assays 523  
molecular markers 523
- molecular typing methods 511
- MRD molecular markers  
BCL-2 IGH 523  
BCR-ABL fusion 523  
CDRIII 523  
DEK-CAN fusion 523  
E2A-HLF fusion 523  
E2A-PBX1 fusion 523  
NPM1 mutation 523  
PML-RARalpha-fusion 523  
SIL-TAL 523  
typing for BMT/SCT 511
- Hodgkin lymphoma (HL)  
113–120
- CIBMTR data 116, 119
- classification 113
- contraindications for  
autologous transplant 120
- DHAP 119
- ESHAP 119
- gemcitabine, dexamethasone  
and cisplatin (GDP) 120
- ICE 119
- indications for allogeneic  
transplant 120
- indications for autologous  
transplant 119–120
- miniBEAM 119
- monitoring posttransplant 120
- prognostic factors 114–115  
conventional therapy  
114–115
- results  
autologous transplant  
115–117  
conventional therapy 115  
conventional therapy in  
adults 115  
myeloablative allogeneic  
transplant 117–118  
nonmyeloablative  
allogeneic transplant  
118–119
- risk factors, early stage/  
advanced 114–115
- staging 114
- hormonal problems, male/  
female 379–380
- human endogenous retrovirus  
(HERV) 154, 156
- human hematopoietic system  
7–13
- human immune system 14–23
- human leukocyte differentiation  
antigens 15
- human marrow  
microenvironment 11  
progenitor–stromal  
interactions 11
- Hunter syndrome (MPSH)  
192
- Hurler syndrome (MPSIH)  
192–193  
factors determining outcome  
after HSCT 196–197  
lysosomal enzyme  
alpha-L-iduronidurase  
deficiency 193  
outcome of transplantation  
198–199
- Hurler–Scheie syndrome  
(MPSIHS) 193
- hydrocodone 415, 419
- hydrocortisone, CNS leukemia  
pretransplant 245
- hydromorphone 415
- hypertension, TA-TMA  
358–359
- hypoxia-inducible transcription  
factors (HIF) 155
- I**
- ICE 119  
Hodgkin lymphoma (HL)  
119  
salvage regimen 95
- idarubicin 466–468
- idiopathic pneumonia  
syndrome (IPS)  
398–399
- alpha-L-iduronidurase  
deficiency 193
- ifosfamide 464–465
- imatinib 58, 218, 390, 494  
chronic GVHD 322
- imipenem/cilastatin 427
- immune deficiency syndromes  
*see* congenital  
immunodeficiencies
- immune neuropathies, acute 393
- immune system 14–23
- immunodeficiencies, congenital  
172–177
- immunosuppressants 483–491  
ATG 315  
neurotoxicity 390  
posttransplant 313
- inborn errors of metabolism  
(IEM) 192–202  
allogeneic HSCT 192  
alternative strategies and  
limitations 201  
CRIM negative infantile  
forms 201  
enzyme replacement/substrate  
reduction therapies  
(ERT/SRT) 201  
factors determining outcome  
after HSCT 196–197  
future perspective 201–202  
indications for HSCT 199  
outcome of HSCT 194  
pediatric BMT transplant  
group (UK), indications  
for HSCT 199T  
planning HSCT 198–199
- indolamine 2,3-dioxygenase  
(IDO) 222
- induced pluripotent stem (IPS)  
cells 223–224
- infections after HSCT 330–346  
antibacterial prophylaxis 345  
antibiotic therapy, empiric 331  
antifungal prophylaxis 345  
antifungal treatment  
notes 341  
for persistent fever 332–333  
systemic 340T  
antiviral prophylaxis 346  
bacteremia 334  
catheter-related bloodstream  
infections (CRBSI)  
335, 335T  
complications 336  
*Clostridium difficile* infection  
(CDI) 338–339, 339T  
cryptococcosis 344  
evaluation 331  
fever  
defined 331  
and neutropenia  
330–334, 334T  
of unknown origin (FUO)  
332–333  
gastrointestinal tract 336T  
head and ENT (HEENT)  
infections 336T

- infections after HSCT (cont.)  
 hepatitis B, exposed or previously infected recipients 342  
 hepatitis C infected recipient 343  
 hepatitis posttransplant 342  
 herpesvirus 341, 342T  
*Legionella* pneumonia 344  
*Mycobacterium avium* complex 344  
 neutropenia, defined 331  
 new fever or suspected infection 331  
 penicillin allergy 332  
*Pneumocystis jirovecii* pneumonia 341, 341T, 345  
 prophylaxis 341T, 345  
 postsplenectomy 343  
 pre-emptive treatment for asymptomatic CMV 346  
 pre-transplant testing for occult infection 344  
 prophylaxis 344  
 respiratory tract 337–338, 338T  
 toxoplasmosis 344  
 treatment 331–333  
 infertility after HSCT 380–384  
 infliximab 498–499  
 action 316  
 acute steroid-refractory GVHD 315–316  
 Ink4 CKI family 13  
 integrins 16  
 intercellular adhesion molecules 16  
 interferon-alpha and GM-CSF 217–218  
 interferon-gamma 221, 302  
 interleukin-2 221, 302  
 interleukin-10 302  
 common haplotypes 299  
 interleukin-11 8  
 International Prognostic Index (IPI) 94–98  
 age-adjusted index (aa-IPI) for aggressive lymphoma 94T, 94F  
 FLIPI 100  
 mantle cell lymphoma (MIPI) 98F, 98, 99T  
 NHL T98–99  
 Revised (R-IPI) 94, 95F  
 involved field radiotherapy (IFRT), posttransplant 98  
 iron overload 376–379  
 irradiation, total body irradiation (TBI) 255–256  
 ITIMs (immunoreceptor tyrosine-based inhibition motifs) 19  
 itraconazole 448–449
- J**  
 joint contractures 385–386
- K**  
 Karnofsky performance score 274  
 ketoconazole 448–449, 456–458  
 cream 456  
 Ki-67 index 99  
 kidney cancer *see* renal cell cancer  
 kidney failure 237  
 killer immunoglobulin receptors (KIRs) 17, 155, 212, 280  
 haploidentical stem cell transplantation 280  
 and ligands 19–20, 280
- L**  
 lacrimal gland, complications of HSCT 373  
 Lansky children's play scale, HCT 275  
 leccams (selectins) 16  
*Legionella* pneumonia 344  
 lenalidomide 125, 130, 134, 499–501  
 chromosome 5q deletion 81  
 MDS, chromosome 5q deletion 81  
 risk of severe GVHD 219  
 lenograstim 8  
 leucovorin, levoleukovorin 501  
 leukapheresis 241, 391  
 chemokines/cytokines 241  
 cryopreservation technique 242  
 minimum cells to collect 241
- mobilization of stem cells 240–241  
 patients who are poor mobilizers 241  
 reasons for poor yields 241  
 venous access 240  
 when to start 240  
 leukemia, acute undifferentiated 29  
 leukemia-specific antigens 212  
 levofloxacin 436  
 linezolid 438–439  
 liver, steroid-refractory acute GVHD 317  
 liver function abnormalities posttransplant 377  
 loperamide 444  
 lung function score 402  
 lymphoblastic lymphoma 105–106  
 lymphoma, conditioning regimens 282  
 lymphoproliferative disorder, posttransplant (PTLD) 363–365  
 lymphotactin 17  
 lysosomal enzyme alpha-L-iduronidase deficiency 193
- M**  
 major histocompatibility complex (MHC) 14  
 antigen presentation 14  
*see also* HLA-testing  
 male fertility/hormonal problems 379–382  
 mammalian target of rapamycin (mTOR) 147  
 alpha-mannosidosis 192  
 mantle cell lymphoma 98–100  
 allogeneic HCT 100  
 autologous transplantation 99–100  
 CALGB report results 100, 100F  
 Ki-67 index 99  
 Mantle Cell International Prognostic Index (MIPI) 98–99, 98F, 99T  
 Maroteaux Lamy syndrome (MPSVI) 192  
 melphalan 125, 465  
 menopause-related symptoms, treatment 380

- menstrual suppression 380  
 meperidine 416, 419  
 2-mercaptoethane sulfonate  
   sodium (MESNA) 254,  
   501–502  
 meropenem 428  
 mesenchymal stem cells  
   (MSCs, MMPCs)  
   20–23, 222–223  
   characteristics 20  
   frequency of differentiation  
   21  
   immune suppressive  
   properties 21  
   phenotype 20  
   purification strategies 22  
   sites of inflammation 21  
   in vitro differentiation 23  
 mesenchymal stromal cells  
   (MSCs) 222  
 MESNA (2-mercaptoethane  
   sulfonate sodium) 254,  
   501–502  
 metabolic encephalopathy,  
   causes 390  
 methadone 416, 419  
 methotrexate 390, 470  
   CNS leukemia pretransplant  
   245  
   glucarpidase 472  
   GVHD prevention 313  
   leucovorin rescue of 471  
 methylprednisolone 166  
   acute GVHD, suggested  
   taper 314  
   aplastic anemia 166  
 methyltransferase inhibitors 474  
 metronidazole 439  
 MGUS, minimum diagnostic  
   criteria 123  
 micofungin 452  
 miconazole 456–457  
 MINE, salvage regimen 95  
 mini-BEAM 119  
 mitoxantrone 466–468  
 molgramostim 8  
 monobactams 431  
 monoclonal antibodies 391  
   chronic GVHD 322  
   steroid-refractory GVHD 315  
   TA-TMA 358  
 morphine 416, 419  
 mouth care, guidelines 268  
 moxifloxacin 436  
 multiple myeloma 122–131  
   adverse prognostic factors 124  
   antibody production 212  
   CIBMTR data 130  
   conditioning regimens 283  
   contraindications for  
   transplant 131  
   indications for transplant  
   130–131  
   international staging system  
   123  
   international uniform  
   response criteria 124  
   maintenance posttransplant  
   131  
   minimum diagnostic  
   criteria 123  
   monitoring posttransplant 131  
   pretransplant workup 131  
   residual or persistent 216T  
   stem cell transplant 219  
   treatment  
     allogeneic transplant 129  
     autologous transplant 3,  
     125–128  
     total therapy 128  
 multiple sclerosis 205–206  
   autologous stem cell  
   transplantation 206  
 muscular complications of  
   HSCT 386–387  
 musculoskeletal complications  
   of HSCT 385–387  
 mustine, extravasation antidote  
   281  
 myalgia 386  
 myasthenic syndromes 388,  
   394–395  
*Mycobacterium avium* complex  
   344  
 mycophenolate mofetil 488  
   GVHD complications  
   prevention 322  
   GVHD prevention 313  
 myeloablative transplantation  
   conditioning regimen 283–284  
   sickle cell disease 189–190  
   Hodgkin lymphoma (HL)  
   117–118  
   vs. reduced-intensity  
   regimen 285–286  
 myelodysplasia (MDS) 77–88  
 myelodysplastic syndrome  
   (MDS) 218–219  
   age of patients at diagnosis  
   87  
   alkylating agents, secondary  
   MDS/AML 80  
 allogeneic transplant 84  
 anthracyclines 80  
 associated with isolated del  
   5q 78  
 autologous transplant 88  
 azacitidine efficacy 81  
 CIBMTR data 86–87  
 contraindications to  
   autologous transplant  
   88  
 conventional treatment  
   options 80  
 cytogenetic abnormalities 79  
 decision analysis, allogeneic  
   bone marrow 84  
 epipodophyllotoxins 80  
 FAB classification 78  
 HLA-identical family  
   member transplant 88  
 HLA-partially matched  
   family/matched  
   unrelated transplant 88  
 indications for transplant  
   87–88  
 International Prognostic  
   Scoring System (IPSS) 79  
   risk groups 79  
 lenalidomide with  
   chromosome 5q  
   deletion 81  
 Markov model 84  
 pretransplant workup 88  
 reduced-intensity  
   conditioning (RIC) 85  
 refractory anemia (RA) 78  
   with excess blasts-1  
   (RAEB-1) 78  
   with excess blasts-2  
   (RAEB-2) 78  
   with ringed sideroblasts  
   (RARS) 78  
 refractory cytopenia with  
   multilineage dysplasia  
   (RCMD) 78  
 refractory cytopenia with  
   multilineage dysplasia  
   and ringed sideroblasts  
   (RCMD-RS) 78  
 results  
   allogeneic transplant  
   83–87  
   autologous transplant 82  
   conventional therapy 81  
   retrospective comparison 85  
 staging and classification  
   78–79

- myelodysplastic syndrome (MDS) (cont.)  
 stem cell source in autologous transplant 82  
 taxanes/cyclophosphamide 80  
 therapy-related (t-MDS) 33, 363  
 unclassified (MDS-U) 78  
 WHO classification 78  
 myeloid aplasia in chronic GVHD 217  
 myeloma *see* multiple myeloma  
 myeloperoxidase (MPO) 28  
 myopathy 386, 388  
 myositis 386, 393, 395
- N**
- nafcillin 432  
 naphthol AS-D chloroacetate esterase (NASD) 28  
 National Marrow Donor Program 525  
 natural killer (NK) cells 17, 212, 220–221  
 activating and inhibitory receptors 17  
 donor recipient NK identity and mismatch 20  
 inhibition and activation 18  
 killer immunoglobulin receptors (KIR) 17, 19–20, 155, 280  
 mismatch 221  
 missing self hypothesis 17  
 phenotype 17  
 nausea/vomiting 374  
 nephrotic syndrome, amyloidosis 135  
 neuroblastoma 160  
 pediatric 160–161  
 neurodegenerative disorders 192  
 neurologic complications of HSCT 387–395  
 causes of epileptic seizures 389  
 neurotoxicity  
 antineoplastic 390  
 calcineurin-related 391–392  
 immunosuppression 390, 393  
 neutropenia 330–333, 334T  
 causes after BMT 384  
 defined 331  
 neutrophil recovery, defined 348
- nifedipine 488  
 nilotinib 58, 494  
 nimodipine  
 contraindications 359  
 cyclosporin-associated blindness 359  
 NOD-like receptors 211  
 non-Hodgkin lymphoma (NHL) 90–108  
 diffuse large B-cell lymphoma (DLBCL) 94–98  
 follicular NHL 100–102  
 International Prognostic Index (IPI) 94–98  
 peripheral T-cell lymphomas (PTCLs) 102–103  
 phenotypic markers and chromosomal translocations 93T  
*see also* diffuse large B-cell lymphoma (DLBCL); mantle cell lymphoma  
 non-SCID immunodeficiencies 173  
 3-year survival 175  
 BMT results 174–176  
 cumulative probability of survival 176  
 nonspecific esterase (NSE) 28  
 norfloxacin 244  
 novel cellular therapies 220–225  
 NSAIDS 414  
 NSGCT *see* testicular tumors (NSGCT)  
 nystatin 455, 457
- O**
- octreotide 444  
 ondansetron 447  
 onychomycosis 458  
 opioids 414–419  
 contraindications and adverse effects 418  
 conversion chart 418  
 oral hygiene 268–269  
 organ-related complications of HSCT 366–369  
 oseltamivir 480  
 osteodensitometry 386  
 osteomyelitis 385  
 osteonecrosis 385  
 osteoporosis 385  
 ovarian failure 381
- oxacillin 432  
 oxycodone 417
- P**
- p13K/Akt/mTOR pathway 13  
 p19, ARF activity 13  
 pain relief 269  
 palifermin 502–503  
 palonosetron 447  
 pazopanib 147  
 pediatrics  
 ALL 44, 52–53  
 AML, indications for transplant 38  
 CML, allogeneic transplant results 62  
 growth and development, and TBI 359–360  
 inborn errors of metabolism (IEM) 199T  
 neuroblastoma 160–161  
 play scale, HCT 275  
 sickle cell disease 187  
 thalassemia 187  
 pegaspargase 477  
 pegfilgrastim 8  
 penicillins 431–434  
 allergy 332  
 contraindications or adverse effects 433  
 drug interactions 433  
 general prescribing information 433  
 pentamidine 244, 440–442  
 pentostatin, steroid-refractory GVHD 315  
 perianal complications of HSCT 396  
 periengraftment respiratory distress syndrome (PERDS) 399–400  
 periodic acid–Schiff (PAS) reaction 28  
 peripheral blood stem cell infusion, autologous 262–263  
 peripheral T-cell lymphomas (PTCLs) 102–103  
 allo-HCT 102  
 auto-HCT 102F  
 Pesaro criteria 189  
 PET 106–107  
 pharmacopoeia 411  
 targeted therapies 491–496  
 Philadelphia chromosome 56

- photopheresis (ECP)  
 acute steroid-refractory  
   GVHD 316  
   mechanism 316  
 piperacillin/tazobactam 426–427  
 plasma cell disorders  
   differential diagnosis 122  
   *see also* multiple myeloma  
 platelet count 271  
 platelet recovery, defined 349  
 platelet refractory patients 266  
 platelet transfusion 265–266  
 platelet-derived growth factor  
   (PDGF) 21  
 pneumonia  
   idiopathic pneumonia  
     syndrome (IPS) 398–399  
   incidence and mortality  
     400–401  
   *Legionella pneumonia* 344  
   *Pneumocystis jirovecii*  
     pneumonia 341, 341T,  
     345  
 polyene macrolides 452–454  
 polymyositis 386  
 polyneuropathy 388, 393  
 polyoma BK virus,  
   hemorrhagic cystitis  
     351–353  
 polyserositis 386  
 posaconazole 448–449  
 posttransplant  
   lymphoproliferative  
   disorders (PTLD) 103,  
   363–365  
 posttransplant surveillance,  
   guidelines 107  
 prednisone 485  
   acute GVHD, suggested  
   taper 314  
 pregabalin 420  
 procarbazine 391  
 progenitor–stromal  
   interactions, human  
   marrow  
   microenvironment 11  
 prophylactic medications for  
   HSCT 244  
 proteinase-3 211  
 psychosocial complications of  
   HSCT 396–397  
   emotional barriers of HSCT  
   396  
   stress, causes 396  
   treatment 397  
 pulmonary, *see also* respiratory  
   pulmonary chronic GVHD/  
     BO/BOS 401  
   diagnostic workup 402  
   NIH consensus project 403  
   risk factors 401–402  
   pulmonary complications of  
     HSCT 397–404  
   bronchoalveolar lavage 403  
   diffuse alveolar hemorrhage  
     (DAH) 400  
   incidence and mortality  
     early 398–399  
     late 400–401  
   lung biopsy 403  
   lung function score 402  
   lung injury 397  
   obstructive lung function  
     changes 402  
   perigraftment respiratory  
     distress syndrome  
     (PERDS) 399–400  
   transbronchial biopsy 403  
   treatment 403  
 pulmonary function testing  
   402  
 pulmonary toxicity 276  
 pyrimidine analogs 454
- R**
- radiation 391  
   total body irradiation (TBI)  
     255–256  
 radiation dose 272  
 radicular disease 387  
 rapamycin inhibitors, target of  
   390  
 rasburicase 503–504  
 readmission to hospital 270  
 red blood cell recovery, defined  
   349  
 red cell alloimmunization 188  
 reduced-intensity conditioning  
   (RIC) 85  
 regulatory T-cells (Treg) 220  
 renal cell cancer 146–156  
   enhancing graft-vs.-RCC  
     155–156  
   future 156  
   graft-vs.-tumor responses  
     148–153  
   long-term disease control 154  
   mechanism of graft-RCC  
     responses 154–155  
   metastatic, allogeneic  
     transplant 152  
   regression of renal  
     metastases 148–153  
   results  
     allogeneic transplant  
       147–154  
     conventional transplant 147  
 renal complications of HSCT  
   404–405  
 renal failure 237  
 renal toxicity 276  
 respiratory, *see also* pulmonary  
 respiratory distress syndrome,  
   graft-associated  
   (PERDS) 399–400  
 respiratory failure 237  
 respiratory tract infections  
   after HSCT 337–338,  
   338T  
 reticulocytosis, TA-TMA 358  
 rheumatoid arthritis 205, 207  
 right atrial catheters  
   245–253  
 ringworm 458  
 rituximab 94F, 96–97, 391,  
   493–494
- S**
- safety switch, cellular therapy  
   224  
 salvage regimens 95  
 San Filippo disease (MPSIII) 193  
 Sandhoff disease 201  
 sarcomas *see* soft tissue  
   sarcomas  
 sargramostim 8  
 Scheie syndrome 193  
 secondary malignancies after  
   HCT for NHL 103  
 secondary malignancies after  
   HSCT 361–366  
   myelodysplastic syndrome 363  
   posttransplant  
     lymphoproliferative  
     disorder (PTLD)  
     363–365  
   prognosis 365–366  
   risk factors 361  
   solid tumors 361T, 361–366  
 selectins 16  
 septic arthritis 385  
 serotonin norpinephrine  
   re-uptake inhibitors  
   (SNRIs) 420–421  
 serotonin-5HT<sub>3</sub> inhibitors  
   446–448

- severe combined immunodeficiency (SCID)  
 3-year survival 175  
 BMT results 173–174  
 cumulative probability of survival 176  
 maternal chimerism 174  
 mutations 173  
 screening 173  
 sick euthyroid syndrome 370  
 sickle cell anemia, outcome 182  
 sickle cell disease  
 allogeneic transplant results 187  
 complications 180  
 contraindications to transplant 188  
 conventional therapy 182  
 indications for transplant 188  
 monitoring posttransplant 190  
 myeloablative or reduced intensity conditioning 189–190  
 pediatric patients, full dose allotransplant results 187  
 related cord blood transplant 185  
 specific precautions during transplant 190  
 sinusoidal obstruction syndrome (SOD) 353  
 sirolimus 489–490  
 GVHD prevention 313  
 skeletal complications of HSCT 385–387  
 skin  
 acute GVHD, steroid-refractory 315, 317  
 dermatologic complications of HSCT 369–370  
 Sly syndrome (MPSVII) 192  
 soft tissue sarcomas 159–162  
 classification 159  
 results with high-dose therapy 159–162  
 solid tumors 139–162  
 sorafenib 147  
 spinal cord disease 387  
 spine pain 385  
 stains, cytochemical and immunohistochemical 28  
 stem cell transplant  
 see hematopoietic (progenitor/stem) cell transplant (HCT)  
 Stem Cell Transplant Outcomes Database 3  
 steroid-refractory acute GVHD 314–315, 317  
 liver 317  
 skin 315, 317  
 steroid-sparing therapies, GVHD 323  
 stomatitis 276  
 streptokinase/urokinase/TPA instillation 252  
 stress, causes 396  
 substrate reduction therapy (SRT) 198  
 altering metabolic pathways 201  
 Sudan Black B (SBB) 28  
 sulfamethoxazole (SZM) 440–443  
 sunitinib 147  
 surface area calculation 271  
 syndrome of inappropriate adrenocorticotrophic hormone secretion (SIADH) 370  
 systemic lupus erythematosus 207
- T**
- T-cell neoplasms, WHO 90T  
 T-cell–B-cell collaboration 14  
 T-cells  
 adoptive immunotherapy 224–225  
 antigen receptor complex (TCR) 15  
 depletion 210  
 transplants 217  
 graft-vs.-leukemia (GVL) effects 147–148  
 GVHD  
 depletion 210  
 regulatory suppression 302  
 lymphocyte tolerance to tumor antigens 224  
 memory T-cells, acute GVHD 302  
 migration of 303  
 proliferation and differentiation in GVHD 301  
 receptors (TCR) 211  
 regulatory T-cells (Treg) 220  
 suicide gene 217  
 Th1/Th2 paradigm of donor T-cells 305  
 tacrolimus 390, 491  
 GVHD complications prevention 322  
 GVHD prevention 313  
 target of rapamycin inhibitors 390  
 Tay–Sachs disease 201  
 temsirolimus 147  
 terbinafine 457  
 drug interactions 458  
 terminal  
 deoxynucleotidyl-transferase (Tdt) 28  
 testicular failure 381  
 testicular tumors (NSGCT) 139–144  
 classification 139  
 conditioning regimens for HCT 283  
 germ cell tumors 139  
 indication for autologous transplant 144  
 monitoring posttransplant 144  
 pretransplant workup 144  
 prognosis, conventional therapy 140  
 results  
 autologous transplant 141–143  
 high-dose chemotherapy 142  
 high-dose chemotherapy and stem cell rescue 143  
 risk factors 143  
 retroperitoneal lymph node dissection (RPLND) 140  
 staging 140  
 tandem vs. single autologous transplant 143  
 testosterone, dosages 380  
 thalassemia  
 contraindications to transplant 188  
 conventional therapy 180–182  
 monitoring posttransplant 190  
 myeloablative or reduced intensity conditioning 189–190  
 pediatric patients, full dose allotransplant results 187

- Pesaro score 189  
 pretransplant workup  
   188–189  
 related cord blood  
   transplant, results 185  
 beta-thalassemia syndromes  
   179  
 unrelated STC transplant  
   results 184  
 thalassemia major  
   allogeneic transplant 184  
   conditioning regimens  
     284  
   indications for transplant 188  
 thalidomide 125, 130, 219, 391,  
   499–501  
 therapy-related myelodysplastic  
   syndrome (t-MDS) 363  
 thiotepa 466  
 thrombocytopenia, causes after  
   BMT 385  
 thrombotic microangiopathy,  
   transplant-associated  
   (TA-TMA) 357–358  
 thyroid, low T3/T4 syndrome  
   370  
 thyroid function tests 370  
 tobramycin 423  
 Toll-like receptors (TLRs) 211,  
   303  
 topoisomerase II inhibitors  
   472–478  
 tositumomab 97  
 total body irradiation (TBI)  
   255–256  
   and growth and development  
     359–360  
   ovarian failure 381  
 total parenteral nutrition  
   267–268  
 toxoplasmosis 344  
 tramadol 417, 419  
 transplant frequency,  
   Europe 3  
 transplant-associated  
   thrombotic  
   microangiopathy  
   (TA-TMA) 357–358  
   diagnostic criteria 357  
   prognosis 358  
   treatment 358  
   transplant-related  
     complications of HSCT  
       348–366  
   transplant-related mortality 4  
   tricyclic antidepressants  
     (TCAs) 421–422  
   trimethoprim (TMP) 244,  
     440–443  
   triple immune suppressive  
     therapy 167  
   tumors 139–162  
     and growth hormone  
       treatment 360  
     secondary malignancies  
       (solid tumors) 361T,  
       361–366  
   tyrosine kinase inhibitors  
     (TKIs) 147, 218, 494  
     CML 3, 58, 61
- U**
- umbilical cord blood (UCB)  
   288–293  
   collection and banking  
     290–291  
   comparison of UCB with  
     matched and  
     mismatched bone  
     marrow 293  
   Cord Blood Forum 526  
   cord blood unit 3  
   favorable outcomes 289  
   graft-vs.-leukemia (GVL)  
     effect 289  
   hematologic malignancies  
     291  
   historical background 288  
   immunologic features  
     289–290  
   neonate maintaining more  
     naïve immune system  
     289  
   recent developments 291–292  
   regulatory framework 290  
   results of cord blood  
     transplant 291  
   summary 292–293  
   T-cell depletion 289  
   trials 289–290  
   US National Cord Blood  
     Inventory 291  
   world-wide units available 288  
   ursodiol (ursodeoxycholic acid)  
     504
- V**
- vaccinations, posttransplant  
   270–271  
 valacyclovir 478, 480  
 valganciclovir 481  
 vancomycin 443–444  
 vascular endothelial growth  
   factor (VEGF) 146  
 venlafaxine 421  
 veno-occlusive disease (VOD)  
   353  
 vertebral disk prolapse 385  
 vinca alkaloids 475–476  
   extravasation antidote 281  
 von Hippel–Lindau (VHL)  
   gene 146  
   inactivation 154  
 voriconazole 448–449
- W**
- white blood cell (WBC) count  
   271  
 WHO, classification of B-cell  
   and T-cell neoplasms  
   90T  
 Wilms tumor antigen 211  
 Wiscott–Aldrich syndrome,  
   impact of donor type on  
   outcome of BMT  
   transplant 175  
 World Marrow Donors  
   Association 526
- X**
- X-linked  
   adrenoleukodystrophy  
   (X-ALD) 192–194
- Z**
- zanamivir 481